Skip to main content

Advertisement

Springer Nature Link
Log in

Identifying menopause in breast cancer patients: considerations and implications

  • Review Paper
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The pivotal role for oestrogen in the aetiology and progression of the majority of breast cancers is well established; consequently, endocrine therapy is an important approach in the treatment of this disease for many women. While tamoxifen has been the mainstay of endocrine therapy for breast cancer for over 30 years, we now have a range of therapeutic manipulations, in particular utilising the aromatase inhibitors (AIs) in post-menopausal women. To date each strategy employing an AI, including primary adjuvant monotherapy, switching from tamoxifen after 2–3 years, and extending adjuvant therapy with an AI after 5 years of tamoxifen, has shown superiority compared with tamoxifen alone; however, AI monotherapy is not suitable for pre- or peri-menopausal women, and therefore, an accurate assessment of the menopausal status of each individual patient is essential. Unfortunately, defining post-menopausal status can be fraught with difficulty, especially when cancer therapy is either recently completed (e.g. chemotherapy), or ongoing (e.g. tamoxifen and/or luteinising hormone-releasing hormone analogues). This paper shall review the definition of menopause in breast cancer patients and explore the issues and implications surrounding such a definition with respect to therapy choice for patient and physician alike.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285

    Article  PubMed  CAS  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Google Scholar 

  3. Clemons M, Coleman RE, Verma S (2004) Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30:325–332

    Article  PubMed  CAS  Google Scholar 

  4. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31:1–17

    Article  PubMed  CAS  Google Scholar 

  5. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryan J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

    Article  PubMed  CAS  Google Scholar 

  6. Gainford MC, McCready D, Cohen Z, Clemons M (2006) The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat 96(3):203–206

    Article  PubMed  CAS  Google Scholar 

  7. Genuth SM (1990) Female reproduction. In: Berne RM, Levy MN (eds) Principle of physiology. Wolfe Publishing Ltd, London, pp. 599–615

    Google Scholar 

  8. Treloar AE, Boynton RE, Behn BG, Brown BW (1967) Variation of the human menstrual cycle through reproductive life. Int J Fertil 12:77–126

    PubMed  CAS  Google Scholar 

  9. Sherman BM, Korenman SG (1975) Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 55:699–706

    Article  PubMed  CAS  Google Scholar 

  10. Shideler SE, DeVane GW, Kalra PS, Benirschke K, Lasley BL (1989) Ovarian–pituitary hormone interactions during the perimenopause. Maturitas 11:331–339

    Article  PubMed  CAS  Google Scholar 

  11. Trevoux R, De Brux J, Castanier M, Nahoul K, Soule JP, Scholler R (1986) Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 8:309–326

    Article  PubMed  CAS  Google Scholar 

  12. Metcalf MG, Donald RA, Livesey JH (1981) Pituitary–ovarian function in normal women during the menopausal transition. Clin Endocrinol (Oxf) 14:245–255

    CAS  Google Scholar 

  13. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in pre-menopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729

    PubMed  CAS  Google Scholar 

  14. Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. N Engl J Med 343:1086–1094

    Article  PubMed  CAS  Google Scholar 

  15. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370

    PubMed  CAS  Google Scholar 

  16. Bhatavdekar JM, Shah NG, Patel DD, Karelia NH, Trivedi SN, Vora HH, Ghosh N, Giri DD, Balar DB (1992) Endocrine function in pre-menopausal and post-menopausal advanced breast cancer patients treated with CMF or tamoxifen. Neoplasma 39:123–127

    PubMed  CAS  Google Scholar 

  17. Delrio G, De Placido S, Pagliarulo C, d’Istria M, Fasano S, Marinelli A, Citarella F, De Sio L, Contegiacomo A, Iaffaioli RV (1986) Hypothalamic–pituitary–ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori 72:53–61

    PubMed  CAS  Google Scholar 

  18. Groom GV, Griffiths K (1976) Effect of the anti-estrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, estradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421–428

    Article  PubMed  CAS  Google Scholar 

  19. West CP, Baird DT (1987) Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. Clin Endocrinol (Oxf) 26:213–220

    CAS  Google Scholar 

  20. Buzzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, Zilembo N, Di Bartolomeo M, Di Leo A, Arcangeli G, Aitini E, Farina G, Schieppati G, Galluzzo D, Martinetti A (1995) Combination goserelin and tamoxifen therapy in pre-menopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. Br J Cancer 71:1111–1114

    PubMed  CAS  Google Scholar 

  21. Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and peri-menopausal women. Eur J Cancer 39:861–869

    Article  PubMed  CAS  Google Scholar 

  22. Tredway DR, Buraglio M, Hemsey G, Denton G (2004) A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, pre-menopausal female volunteers. Fertil Steril 82:1587–1593

    Article  PubMed  CAS  Google Scholar 

  23. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23:4347–4353

    Article  PubMed  CAS  Google Scholar 

  24. Smith IE, Dowsett M, Yap TS, Walsh G, Lonning PE, Santen RJ, et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea; caution and suggested guidelines. J Clin Oncol 24(16):2444–2447

    Article  PubMed  CAS  Google Scholar 

  25. Carlson RW, Schurman CM, Rivera E, Chung CT, Phan S-C, Dice EK, Arun B, Thomas E, Valero V (2004) Goserelin plus anastrozole for the treatment of pre-menopausal women with hormone receptor positive, recurrent/metastatic breast cancer. Breast Cancer Res Treat 88:S237

    Google Scholar 

  26. Forward DP, Cheung KL, Jackson L, Robertson JFR (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for pre-menopausal advanced breast cancer. Br J Cancer 90:590–594

    Article  PubMed  CAS  Google Scholar 

  27. National Comprehensive Cancer Network (2005) NCCN practice guidelines in oncology v.1.2005: breast cancer. http://www.nccn.org

  28. World Health Organization (1981) Technical report series: research on the menopause. WHO Technical Report Series No. 670. Geneva, Switzerland

  29. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article  PubMed  CAS  Google Scholar 

  30. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Propiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Dsitante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138–5147

    Article  PubMed  CAS  Google Scholar 

  31. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingstone RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in post-menopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  PubMed  CAS  Google Scholar 

  32. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) Switching of post-menopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  PubMed  CAS  Google Scholar 

  33. The ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  Google Scholar 

  34. Cooper GS, Baird DD, Darden FR (2001) Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population-based study of women aged 35–49 years. Am J Epidemiol 153:1159–1165

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The author wishes to thank Dr Martin Quinn, from Complete Medical Communications, who provided medical writing support.

Author information

Authors and Affiliations

  1. Division of Medical Oncology/Haematology, Princess Margaret Hospital, Suite 5-205, 610 University Avenue, M5G 2M9, Toronto, ON, Canada

    Mark Clemons & Christine Simmons

Authors
  1. Mark Clemons
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Christine Simmons
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Mark Clemons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clemons, M., Simmons, C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 104, 115–120 (2007). https://doi.org/10.1007/s10549-006-9401-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9401-y

Keywords